Lv3
326 积分 2024-12-05 加入
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
3小时前
待确认
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
3小时前
已完结
Claudin 18.2 as a novel therapeutic target
10天前
已完结
Macrophages protect against sensory axon loss in peripheral neuropathy
4个月前
已完结
Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies
4个月前
已完结
Active learning-assisted directed evolution
4个月前
已完结
TREM2 promotes the formation of a tumor-supportive microenvironment in hepatocellular carcinoma
4个月前
已完结
Pyramid Knowledge Distillation for Efficient Human Pose Estimation
4个月前
已关闭
A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells
5个月前
已完结
Ligand interaction landscape of transcription factors and essential enzymes in E. coli
5个月前
已完结
皖公网安备34019202002308
